Analysis of caffeine and paraxanthine in human saliva with ultra-high-performance liquid chromatography for CYP1A2 phenotyping

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 995-996, Issue , 2015, Pages 70-73

  Jordan, Nan Yeun ^a   Mimpen, Jolet Y ^a   van den Bogaard, Willie J M ^a   Flesch, Frits M ^a   van de Meent, Michiel H M ^a   Torano, Javier Sastre ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Caffeine; CYP1A2; Paraxanthine; Phenotyping; Saliva; UHPLC

Indexed keywords

BODY FLUIDS; CAFFEINE; CHROMATOGRAPHY; EXTRACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUIDS; ROOM AND PILLAR MINING;

CYP1A2; PARAXANTHINE; PHENOTYPING; SALIVA; UHPLC;

LIQUID CHROMATOGRAPHY;

ACETIC ACID ETHYL ESTER; CAFFEINE; CYTOCHROME P450 1A2; PARAXANTHINE; 1,7-DIMETHYLXANTHINE; CYP1A2 PROTEIN, HUMAN; THEOPHYLLINE;

ARTICLE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID LIQUID EXTRACTION; MEASUREMENT ACCURACY; PHENOTYPE; PRIORITY JOURNAL; SALIVA; SIGNAL NOISE RATIO; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; CHEMISTRY; CLASSIFICATION; METABOLISM; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL;

CAFFEINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP1A2; HUMANS; LINEAR MODELS; PHENOTYPE; REPRODUCIBILITY OF RESULTS; SALIVA; SENSITIVITY AND SPECIFICITY; THEOPHYLLINE;

EID: 84930639622     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2015.05.020     Document Type: Article

References (15)

1. Meyer U.A. Overview of enzymes of drug metabolism. J. Pharmacokinet. Biopharm. 1996, 24:449-459. 10.1007/BF02353473.
2. Shirley K.L., Hon Y.Y., Penzak S.R., Lam Y.W.F., Spratlin V., Jann M.W. Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers. Neuropsychopharmacology 2003, 28:961-966. 10.1038/sj.npp.1300123.
3. Fuhr U., Rost K.L., Engelhardt R., Sachs M., Liermann D., Belloc C., Beaune P., Janezic S., Grant D., Meyer U.A., Staib A.H. Evaluation of caffeine as a test drug for CYPIA2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics 1996, 6:159-176. 10.1097/00008571-199604000-00003.
4. Faber M.S., Jetter A., Fuhr U. Assessment of CYP1A2 activity in clinical practice: why how, and when?. Basic Clin. Pharmacol. Toxicol. 2005, 97:125-134. 10.1111/j.1742-7843.2005.pto_973160.x.
5. Gu L., Gonzalez F.J., Kalow W., Tang B.K. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cdna-expressed human Cyp1a2 and Cyp2e1. Pharmacogenetics 1992, 2:73-77. 10.1097/00008571-199204000-00004.
6. Perera V., Gross A.S., McLachlan A.J. Measurement of CYP1A2 activity: a focus on caffeine as a probe. Curr. Drug Metab. 2012, 13:667-678.
7. Perera V., Gross A.S., McLachlan A.J. Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma. Biomed. Chromatogr. 2010, 24:1136-1144. 10.1002/bmc.1419.
8. Fuhr U., Rost K.L. Simple and reliable Cyp1a2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics 1994, 4:109-116. 10.1097/00008571-199406000-00001.
9. Hakooz N.M.K. Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2 xanthine oxidase and CYP2A6 enzymatic activities. Curr. Drug Metab. 2009, 10:329-338.
10. Badcock N. Simpler measurement of caffeine and paraxanthine in saliva. Clin. Chem. 1990, 36:391.
11. Tse F.L.S., Szeto D.W. Reversed-phase high-performance liquid-chromatographic determination of caffeine and its N-demethylated metabolites in dog plasma. J. Chromatogr. 1981, 226:231-236. 10.1016/S0378-4347(00)84227-9.
12. Marr J.G.D., Seaton G.G.R., Clark B.J., Fell A.F. Multiple absorbency ratio correlation - a new approach for assessing peak purity in liquid-chromatography. J. Chromatogr. 1990, 506:289-301. 10.1016/S0021-9673(01)91585-7.
13. Vanaerde P., Moerman E., Vanseveren R., Braeckman P. Determination of plasma theophylline by straight-phase high-performance liquid-chromatography - elimination of interfering caffeine metabolites. J. Chromatogr. 1981, 222:467-474. 10.1016/S0378-4347(00)84148-1.
14. Perera V., Gross A.S., Xu H., McLachlan A.J. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics. J. Pharm. Pharmacol. 2011, 23:1161-1168. 10.1111/j.2042-7158.2011.01326.x.
15. Djordjevic R., Ghotbi L., Jankovic S., Aklillu E. Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes. Eur. J. Clin. Pharmacol. 2008, 64:381-385. 10.1007/s00228-007-0438-6.